Recent

% | $
Quotes you view appear here for quick access.

SunTrust Banks, Inc. Message Board

jwrye 340 posts  |  Last Activity: Feb 24, 2015 9:58 AM Member since: Jul 29, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Medicago Awarded Contract by US Department of Health and Human Services to Explore Alternate Production Methods for Ebola Antibodies
    Last update: 24/02/2015 6:42:05 am
    Could be seen as competitor to iBio

  • Reply to

    AST or BTX

    by jwrye Feb 20, 2015 1:18 PM
    jwrye jwrye Feb 20, 2015 2:04 PM Flag

    Thanks!

  • Which would be more prudent? Add to my small AST position that I picked up on the Geron deal or buy some BTX.

  • Reply to

    Huge volume and falling price is a bad combo

    by finchfuller Feb 18, 2015 2:15 PM
    jwrye jwrye Feb 18, 2015 2:19 PM Flag

    This is less than half the volume of the previous 3 days volume when the stock went up.

  • 10Q Filled 11/07/2014
    Balance Sheet-Investment in iBio, Inc. 9/30/14 $532,000 6/30/14 $532,000
    Investment in iBio, Inc. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it initially retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. To date, there were cumulative impairment charges of $298. The market value of the iBio Stock as of September 30, 2014 was approximately $0.7 million. Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and has continued to have a trading price less than $0.88 through October 10, 2014. Since then and through November 7, 2014, the trading price of the iBio Stock has traded above $0.88. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt). As of November 7, 2014, the Company has not sold any shares of the iBio Stock and PNC has not required the Company to sell any of the iBio Stock but continues to reserve the right to do so at any time in the future

  • Reply to

    The Street Sweeper

    by jwrye Feb 17, 2015 12:41 PM
    jwrye jwrye Feb 17, 2015 12:52 PM Flag

    http://www.thestreetsweeper.org/undersurveillance/iBio__Capitalizing_on_Ebola_Misunderstanding
    They didn't disclose at what price they went short.

  • Important Disclosure: The owners of TheStreetSweeper hold a short position in IBIO and stand to profit on any future declines in the stock price.

  • jwrye jwrye Feb 17, 2015 10:53 AM Flag

    NASDAQ Listed 8th

  • jwrye by jwrye Feb 17, 2015 10:41 AM Flag

    10Q Filled 11/07/2014
    Balance Sheet-Investment in iBio, Inc. 9/30/14 $532,000 6/30/14 $532,000
    Investment in iBio, Inc. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it initially retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. To date, there were cumulative impairment charges of $298. The market value of the iBio Stock as of September 30, 2014 was approximately $0.7 million. Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and has continued to have a trading price less than $0.88 through October 10, 2014. Since then and through November 7, 2014, the trading price of the iBio Stock has traded above $0.88. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt). As of November 7, 2014, the Company has not sold any shares of the iBio Stock and PNC has not required the Company to sell any of the iBio Stock but continues to reserve the right to do so at any time in the future.

  • 10Q Filled 11/07/2014
    Balance Sheet-Investment in iBio, Inc. 9/30/14 $532,000 6/30/14 $532,000
    Investment in iBio, Inc. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it initially retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. To date, there were cumulative impairment charges of $298. The market value of the iBio Stock as of September 30, 2014 was approximately $0.7 million. Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and has continued to have a trading price less than $0.88 through October 10, 2014. Since then and through November 7, 2014, the trading price of the iBio Stock has traded above $0.88. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt). As of November 7, 2014, the Company has not sold any shares of the iBio Stock and PNC has not required the Company to sell any of the iBio Stock but continues to reserve the right to do so at any time in the future.

  • jwrye by jwrye Feb 16, 2015 6:37 PM Flag

    This co spun off iBio and still holds a substantial investment in their stock. Why hasn’t their stock moved?

  • Asterias Biotherapeutics Announces Public Offering of Common Stock

  • Reply to

    $7.94/share

    by eric10847 Nov 21, 2014 9:25 AM
    jwrye jwrye Nov 21, 2014 9:37 AM Flag

    Is it time to add?

  • Reply to

    INBP owns IBIO!

    by svnvms Oct 17, 2014 9:39 AM
    jwrye jwrye Oct 20, 2014 3:02 PM Flag

    There are 2 or 3 other larger companies mentioned on CNBC a few minutes ago developing drugs to fight the virus and they are all selling off. I don't why but the niche group is down as a whole.

  • Reply to

    up today

    by jwrye Oct 16, 2014 11:55 AM
    jwrye jwrye Oct 20, 2014 2:40 PM Flag

    miner

  • jwrye by jwrye Oct 16, 2014 11:55 AM Flag

    Does GG have any interest in this quality minor? I hope so.

    Sentiment: Buy

  • jwrye jwrye Aug 15, 2014 1:28 PM Flag

    It looks to me like they are not detailing or disclosing the administrating costs of running the company.
    Admin costs are typically management and executive compensation and everything that goes with it.
    In addition some other salaries and related support like the executive or home offices etc. A question is what percentage of the various aspects of the company should they be?

  • Any ideas as to who and when GG may take a run at?

    Sentiment: Strong Buy

  • Reply to

    Why is NM dropping?

    by dean2013 Jul 8, 2014 1:10 PM
    jwrye jwrye Jul 11, 2014 3:05 PM Flag

    Check the earnings report out today. Top line revenue was off by 100+million which effected the bottom line.

  • I hope there is decent management at Kerr. ABGFF was a complete disaster in my portfolio.

STI
44.34-0.35(-0.78%)Jul 31 4:07 PMEDT